Company

Scholar Rock Exec Says Its First Drug To Target Muscle Loss In Spinal Muscular Atrophy Has A Wholesale Acquisition Cost Of $11,659 For A Single Use Vial; Exec Says Co Expects The Annual Net Cost In The U.S. For A Typical Patient To Be ~$310,000

Sep 14, 2026 · 08:29 AM ET· updated 55m ago

- Conference Call

Why It Matters

Scholar Rock said its new medicine for muscle loss will cost about $310,000 per year. When a company sets a high price, watch to see if insurance companies will pay.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

SRRK57.90

+2.49 (+4.49%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.

Scholar Rock Exec Says Its First Drug To Target Muscle Loss In Spinal Mus­cu­lar At­ro­phy Has A Wholesale Acquisition Cost Of $11,659 For A Single Use Vial; Exec Says Co Expects The Annual Net Cost In The U.S. For A Typical Patient To Be ~$310,000

Scholar Rock Exec Says Its First Drug To Target Muscle Loss In Spinal Muscular Atrophy Has A Wholesale Acquisition Cost Of $11,659 For A Single Use Vial; Exec Says Co Expects The Annual Net Cost In The U.S. For A Typical Patient To Be ~$310,000